Related Experiment Video
Updated: Jul 15, 2026
Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
Published on: October 14, 2019
New developments in the treatment of gastrointestinal neuroendocrine tumors
1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. matthew_kulke@dfci.harvard.edu
Abstract:
Patients with metastatic gastrointestinal neuroendocrine tumors have traditionally been faced with few effective treatment options. Somatostatin analogs often successfully control symptoms of hormonal hypersecretion but seldom result in tumor regression. Some patients with hepatic metastases are also candidates for ablative therapies such as surgical debulking or embolization. The role of systemic agents such as interferon alfa or cytotoxic chemotherapy remains ill defined. The more prevalent use of these modalities has been restricted by low tumor response rates and the potential for toxicity. Novel agents, including radiolabeled somatostatin analogs, inhibitors of the vascular endothelial growth factor pathway, and inhibitors of mammalian target of rapamycin, have shown promising activity in recent clinical studies. Continued investigation of these agents should render a better understanding of their efficacy in patients with advanced neuroendocrine tumors.
Insights
Few treatments exist for metastatic gastrointestinal neuroendocrine tumors. Novel agents like radiolabeled somatostatin analogs show promise for tumor regression and improved patient outcomes.
Area of Science:
- Oncology
- Medical Science
Background:
- Metastatic gastrointestinal neuroendocrine tumors (GI-NETs) present limited therapeutic options.
- Traditional treatments like somatostatin analogs manage symptoms but rarely induce tumor regression.
- Hepatic metastases may be treated with ablative therapies, but systemic options have unclear roles and significant toxicities.
Purpose of the Study:
- To review the current treatment landscape for metastatic GI-NETs.
- To highlight the limitations of existing therapies.
- To discuss emerging novel agents with promising activity.
Main Methods:
- Literature review of clinical studies on metastatic GI-NET treatments.
- Analysis of traditional systemic agents (interferon alfa, chemotherapy) and their efficacy.
- Evaluation of novel therapeutic strategies, including targeted therapies.
Main Results:
- Somatostatin analogs are effective for symptom control but not tumor regression.
- Systemic agents like interferon alfa and chemotherapy have limited response rates and toxicity concerns.
- Novel agents targeting vascular endothelial growth factor and mammalian target of rapamycin pathways show promising activity.
Conclusions:
- Advanced neuroendocrine tumors require innovative treatment strategies.
- Novel agents demonstrate potential for improved efficacy in metastatic GI-NETs.
- Further research is crucial to define the role of these new therapies.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers